Drug intelligence / Profile preview

Encore

Development stage: Unknown
Lead developer: Shanghai Sunway Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral Injection

Overview

Encore (安柯瑞) is a recombinant human adenovirus type 5 injection, genetically engineered with deletions in the E1B-55kD and E3 regions. This oncolytic virus is designed to selectively infect and replicate within tumor cells, leading to their direct lysis while sparing healthy tissues. Beyond direct tumor cell destruction, Encore also stimulates the host's anti-tumor immune response, contributing to its therapeutic effect. Developed in China, it was approved in 2005 by the CFDA for the treatment of advanced nasopharyngeal carcinoma.

Brand names: Encore安柯瑞
Other names: Recombinant Human Adenovirus 5 Injection重组人5型腺病毒注射液

Beyond the preview

Go deeper on Encore.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Encore.

Explore the full profile